Meridian Bioscience Reports Strong Fourth Quarter and Record Full-Year Fiscal 2020 Operating Results and Provides Fiscal 2021 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. FDX
2. CBRS
3. KBH
4. HON
5. MRK
6. HTZ
7. INFY
8. HONA
9. TTWO
10. USO

Go back to Meridian Bioscience Reports Strong Fourth Quarter and Record Full-Year Fiscal 2020 Operating Results and Provides Fiscal 2021 Guidance

Meridian Bioscience (VIVO) Reports Q4 EPS of $0.19, Offers FY21 Guidance

November 13, 2020 7:34 AM EST

Meridian Bioscience (NASDAQ: VIVO) reported Q4 EPS of $0.19, versus $0.14 consensus. Revenue for the quarter came in at $64.2 million, versus $59.6 million consensus.

GUIDANCE:

Meridian Bioscience sees FY2021 EPS of $1.14-$1.28, versus the consensus of $1.02. Meridian Bioscience sees FY2021 revenue of $290-310... More